Axcella Health Inc. (AXLA)

NASDAQ: AXLA · IEX Real-Time Price · USD
0.670
-0.010 (-1.47%)
At close: Feb 1, 2023, 4:00 PM
0.683
+0.012 (1.87%)
Pre-market: Feb 2, 2023, 8:42 AM EST
-1.47%
Market Cap 49.28M
Revenue (ttm) n/a
Net Income (ttm) -76.08M
Shares Out 73.55M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 205,310
Open 0.679
Previous Close 0.680
Day's Range 0.633 - 0.683
52-Week Range 0.162 - 2.890
Beta 1.19
Analysts Buy
Price Target 7.31 (+991.05%)
Earnings Date Mar 20, 2023

About AXLA

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 59
Stock Exchange NASDAQ
Ticker Symbol AXLA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AXLA stock is "Buy." The 12-month stock price forecast is $7.31, which is an increase of 991.05% from the latest price.

Price Target
$7.31
(991.05% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is Axcella Health (AXLA) Stock Up 66% Today?

Axcella Health (NASDAQ: AXLA) stock is rocketing higher on Tuesday after revealing a regulatory path to registration for AXA1125. Investors will note that AXA1125 is the company's treatment for Long ...

1 week ago - InvestorPlace

Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenou...

1 week ago - Business Wire

Axcella Announces Program Reprioritization and Corporate Restructuring

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulato...

1 month ago - Business Wire

Axcella Health Inc. (AXLA) Loses 47.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Axcella Health Inc. (AXLA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...

2 months ago - Zacks Investment Research

Axcella's stock is up 10% after sharing new data for its NASH treatment

Shares of Axcella Therapeutics Inc. AXLA, +6.79% gained 10.9% in premarket trading on Thursday after the biotech said its experimental treatment for nonalcoholic steatohepatitis (NASH) showed statisti...

4 months ago - Market Watch

Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...

4 months ago - Business Wire

Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...

5 months ago - Business Wire

Axcella Reports Second Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...

6 months ago - Business Wire

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Other symbols: ABSIDICEFRLNPLRX
6 months ago - Zacks Investment Research

Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous ...

6 months ago - Business Wire

Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program

Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 stu...

8 months ago - Zacks Investment Research

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...

9 months ago - Business Wire

Axcella Reports First Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...

9 months ago - Business Wire

Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...

11 months ago - Business Wire

Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...

11 months ago - Business Wire

Insiders Buy Over $7M Of 3 Penny Stocks

The US Federal Reserve, on Wednesday, raised its target fed funds rate by 0.25%, its first interest rate hike since 2018. Investors, meanwhile, focused on some notable insider trades When insiders pur...

Other symbols: DMMMLP
11 months ago - Benzinga

Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...

11 months ago - Business Wire

Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...

1 year ago - Business Wire

Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...

1 year ago - Business Wire

Axcella Therapeutics Announces Appointment of New Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...

1 year ago - Business Wire